NSAIDs vs placebo
Minor bleeding · people with superficial thrombophlebitis of the leg
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
74 questions · 76 findings · 31 reviews
No studies found 14 · 18.4%GRADE not reported 9 · 11.8%Very low 16 · 21.1%Low 18 · 23.7%Moderate 13 · 17.1%High 6 · 7.9%
Fondaparinux vs placebo
Minor bleeding · people with ST of the leg
Fondaparinux showed no clear difference in minor bleeding compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.49 [0.53, 4.17]1 study · 2987 participantsModerate
Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis
Minor bleeding · patients with active cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in minor bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes onlyRR 0.83 [0.57, 1.23]4 studies · 1055 participantsLow
Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis
Minor bleeding · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis probably leads to higher minor bleeding compared with low molecular weight heparin secondary prophylaxis (moderate certainty).
1 finding from 1 review
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes onlyRR 1.58 [1.15, 2.16]5 studies · 2854 participantsModerate
LMWH prophylaxis vs fondaparinux prophylaxis
Minor bleeding · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in minor Bleeding compared with fondaparinux prophylaxis (low certainty).
1 finding from 1 review
- Anticoagulation for perioperative thromboprophylaxis in people with cancer 2018 · Cochrane Headline outcomes onlyRR 0.83 [0.34, 2.05]2 studies · 398 participantsLow
LMWH prophylaxis vs UFH
Minor bleeding · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in minor bleeding compared with UFH prophylaxis (moderate certainty).
1 finding from 1 review
- Anticoagulation for perioperative thromboprophylaxis in people with cancer 2018 · Cochrane Headline outcomes onlyRR 1.01 [0.76, 1.33]2 studies · 1194 participantsModerate
Aspirin vs placebo
Minor bleeding · people with antiphospholipid antibodies and no history of thrombosis
ASA showed no clear difference in bleeding ‐ minor compared with placebo (low certainty).
1 finding from 1 review
- Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes onlyRR 3.13 [0.34, 29.01]1 study · 98 participantsLow
clopidogrel plus aspirin vs aspirin
Minor bleeding · people with coronary disease, ischaemic cerebrovascular disease, peripheral arterial disease or at high risk of atherothrombotic disease
clopidogrel plus aspirin probably leads to higher minor bleeding compared with aspirin alone (moderate certainty).
1 finding from 1 review
- Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events 2017 · Cochrane Headline outcomes onlyRR 2.03 [1.75, 2.36]8 studies · 14731 participantsModerate
Heparin prophylaxis vs no prophylaxis
Minor bleeding
Heparin prophylaxis leads to higher minor bleeding compared with no prophylaxis (high certainty).
1 finding from 1 review
- Parenteral anticoagulation in ambulatory patients with cancer 2017 · Cochrane Headline outcomes onlyRR 1.7 [1.13, 2.55]16 studies · 9245 participantsHigh
DOAC vs variable dose warfarin
Minor bleeding · atrial fibrillation patients with CKD
Direct oral anticoagulants (DOAC) showed no clear difference in minor bleeding compared with warfarin (low certainty).
1 finding from 1 review
- Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation… 2017 · Cochrane Headline outcomes onlyRR 0.97 [0.58, 1.61]2 studies · 3012 participantsLow
Intervention not reported
Minor bleeding [ · patients with polycythaemia vera
The intervention probably leads to higher minor bleeding [ (moderate certainty).
1 finding from 1 review
- Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia 2013 · Cochrane Headline outcomes onlyOR 1.852 studies · 630 participantsModerate
Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis
Minor GI bleeding · patients with cancer with venous thromboembolism
It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes minor GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).
1 finding from 1 review
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes onlyRR 1.37 [0.41, 4.64]2 studies · 1495 participantsVery low
Low molecular weight heparin vs unfractionated heparin
Minor bleeding · adults with kidney failure treated with long‐term HD
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis
Minor non‐GI bleeding · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis probably leads to higher minor non‐GI bleeding compared with low molecular weight heparin secondary prophylaxis (moderate certainty).
1 finding from 1 review
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes onlyRR 2.37 [1.44, 3.89]2 studies · 1495 participantsModerate
Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis
Minor upper GI bleeding · patients with cancer with venous thromboembolism
It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes minor upper GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).
1 finding from 1 review
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes onlyRR 1.03 [0.04, 25.97]2 studies · 1495 participantsVery low
Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis
Minor lower GI bleeding · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in minor lower GI bleeding compared with low molecular weight heparin secondary prophylaxis (low certainty).
1 finding from 1 review
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes onlyRR 1.54 [0.72, 3.27]2 studies · 1495 participantsLow
Factor Xa inhibitors vs Anticoagulants
Minor bleeding · Anticoagulants in ACS
Factor Xa inhibitors showed no clear difference in minor bleeding at 30 days compared with anticoagulants (high certainty).
3 findings from 1 review
- RR 0.7 [0.14, 3.39]2 studies · 20404 participantsHigh
- RR 1.76 [0.52, 5.94]1 study · 326 participantsModerate
- RR 0.34 [0.28, 0.43]1 study · 20078 participantsHigh
NMES vs no prophylaxis
Bleeding (major and minor) · participants at risk of venous thromboembolism
1 finding from 1 review
- Neuromuscular electrical stimulation for the prevention of venous thromboembolism 2017 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 576 participantsGRADE not reported
NMES vs low‐dose heparin
Bleeding (major and minor) · participants at risk of venous thromboembolism
1 finding from 1 review
- Neuromuscular electrical stimulation for the prevention of venous thromboembolism 2017 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 194 participantsGRADE not reported
NMES vs Dextran 40
Bleeding (major and minor) · participants at risk of venous thromboembolism
1 finding from 1 review
- Neuromuscular electrical stimulation for the prevention of venous thromboembolism 2017 · Cochrane Headline outcomes onlyno estimate extracted1 study · 72 participantsGRADE not reported